A composition comprising an anti-LAG-3 antibody molecule and an anti-PD-1 antibody molecule, wherein the anti-LAG-3 antibody molecule comprises: (a) a heavy chain variable region comprising a VHCDR1 amino acid sequence of SEQ ID NO: 4, a VHCDR2 amino acid sequence of SEQ ID NO: 5, and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a light chain variable region comprising a VLCDR1 amino acid sequence of SEQ ID NO: 13, a VLCDR2 amino acid sequence of SEQ ID NO: 14, and a VLCDR3 amino acid sequence of SEQ ID NO: 15; (b) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 1; a VHCDR2 amino acid sequence of SEQ ID NO: 2; and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 10, a VLCDR2 amino acid sequence of SEQ ID NO: 11, and a VLCDR3 amino acid sequence of SEQ ID NO: 12; (c) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 286, a VHCDR2 amino acid sequence of SEQ ID NO: 5, and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 13, a VLCDR2 amino acid sequence of SEQ ID NO: 14, and a VLCDR3 amino acid sequence of SEQ ID NO: 15; or (d) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 286; a VHCDR2 amino acid sequence of SEQ ID NO: 2; and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 10, a VLCDR2 amino acid sequence of SEQ ID NO: 11, and a VLCDR3 amino acid sequence of SEQ ID NO: 12, and wherein the anti-PD-1 antibody molecule comprises: (a) a VH comprising a VHCDR1 amino acid sequence of GYTFTTY (SEQ ID NO: 4 from US 2015/0210769), a VHCDR2 amino acid sequence of YPGTGG (SEQ ID NO: 5 from US 2015/0210769), and a VHCDR3 amino acid sequence of WTTGTGAY (SEQ ID NO: 3 from US 2015/0210769); and a light chain variable region comprising a VLCDR1 amino acid sequence of SQSLLDSGNQKNF (SEQ ID NO: 13 from US 2015/0210769), a VLCDR2 amino acid sequence of WAS (SEQ ID NO: 14 from US 2015/0210769), and a VLCDR3 amino acid sequence of DYSYPY (SEQ ID NO: 33 from US 2015/0210769); or (b) a VH comprising a VHCDR1 amino acid sequence chosen from TYWMH (SEQ ID NO: 1 from US 2015/0210769); a VHCDR2 amino acid sequence of NIYPGTGGSNFDEKFKN (SEQ ID NO: 2 from US 2015/0210769); and a VHCDR3 amino acid sequence of WTTGTGAY (SEQ ID NO: 3 from US 2015/0210769); and a VL comprising a VLCDR1 amino acid sequence of KSSQSLLDSGNQKNFLT (SEQ ID NO: 10 from US 2015/0210769), a VLCDR2 amino acid sequence of WASTRES (SEQ ID NO: 11 from US 2015/0210769), and a VLCDR3 amino acid sequence of QNDYSYPYT (SEQ ID NO: 32 from US 2015/0210769). (a) a heavy chain variable region comprising a VHCDR1 amino acid sequence of SEQ ID NO: 4, a VHCDR2 amino acid sequence of SEQ ID NO: 5, and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a light chain variable region comprising a VLCDR1 amino acid sequence of SEQ ID NO: 13, a VLCDR2 amino acid sequence of SEQ ID NO: 14, and a VLCDR3 amino acid sequence of SEQ ID NO: 15; (b) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 1; a VHCDR2 amino acid sequence of SEQ ID NO: 2; and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 10, a VLCDR2 amino acid sequence of SEQ ID NO: 11, and a VLCDR3 amino acid sequence of SEQ ID NO: 12; (c) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 286, a VHCDR2 amino acid sequence of SEQ ID NO: 5, and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 13, a VLCDR2 amino acid sequence of SEQ ID NO: 14, and a VLCDR3 amino acid sequence of SEQ ID NO: 15; or (d) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 286; a VHCDR2 amino acid sequence of SEQ ID NO: 2; and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 10, a VLCDR2 amino acid sequence of SEQ ID NO: 11, and a VLCDR3 amino acid sequence of SEQ ID NO: 12, and (a) a VH comprising a VHCDR1 amino acid sequence of GYTFTTY (SEQ ID NO: 4 from US 2015/0210769), a VHCDR2 amino acid sequence of YPGTGG (SEQ ID NO: 5 from US 2015/0210769), and a VHCDR3 amino acid sequence of WTTGTGAY (SEQ ID NO: 3 from US 2015/0210769); and a light chain variable region comprising a VLCDR1 amino acid sequence of SQSLLDSGNQKNF (SEQ ID NO: 13 from US 2015/0210769), a VLCDR2 amino acid sequence of WAS (SEQ ID NO: 14 from US 2015/0210769), and a VLCDR3 amino acid sequence of DYSYPY (SEQ ID NO: 33 from US 2015/0210769); or (b) a VH comprising a VHCDR1 amino acid sequence chosen from TYWMH (SEQ ID NO: 1 from US 2015/0210769); a VHCDR2 amino acid sequence of NIYPGTGGSNFDEKFKN (SEQ ID NO: 2 from US 2015/0210769); and a VHCDR3 amino acid sequence of WTTGTGAY (SEQ ID NO: 3 from US 2015/0210769); and a VL comprising a VLCDR1 amino acid sequence of KSSQSLLDSGNQKNFLT (SEQ ID NO: 10 from US 2015/0210769), a VLCDR2 amino acid sequence of WASTRES (SEQ ID NO: 11 from US 2015/0210769), and a VLCDR3 amino acid sequence of QNDYSYPYT (SEQ ID NO: 32 from US 2015/0210769).